AR018501A1 - Derivados de la dolastatina 15 - Google Patents

Derivados de la dolastatina 15

Info

Publication number
AR018501A1
AR018501A1 ARP980103445A ARP980103445A AR018501A1 AR 018501 A1 AR018501 A1 AR 018501A1 AR P980103445 A ARP980103445 A AR P980103445A AR P980103445 A ARP980103445 A AR P980103445A AR 018501 A1 AR018501 A1 AR 018501A1
Authority
AR
Argentina
Prior art keywords
group
amino
formula
present
amino group
Prior art date
Application number
ARP980103445A
Other languages
English (en)
Spanish (es)
Original Assignee
Abbott Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Gmbh & Co Kg filed Critical Abbott Gmbh & Co Kg
Publication of AR018501A1 publication Critical patent/AR018501A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00Preparation of compounds containing saccharide radicals
    • C12P19/26Preparation of nitrogen-containing carbohydrates
    • C12P19/28N-glycosides
    • C12P19/30Nucleotides
    • C12P19/34Polynucleotides, e.g. nucleic acids, oligoribonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
ARP980103445A 1997-07-18 1998-07-15 Derivados de la dolastatina 15 AR018501A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/896,394 US6143721A (en) 1997-07-18 1997-07-18 Dolastatin 15 derivatives

Publications (1)

Publication Number Publication Date
AR018501A1 true AR018501A1 (es) 2001-11-28

Family

ID=25406130

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980103445A AR018501A1 (es) 1997-07-18 1998-07-15 Derivados de la dolastatina 15

Country Status (32)

Country Link
US (6) US6143721A (enExample)
EP (1) EP0991658B1 (enExample)
JP (4) JP4508413B2 (enExample)
KR (1) KR100579748B1 (enExample)
CN (1) CN1268636C (enExample)
AR (1) AR018501A1 (enExample)
AT (1) ATE314387T1 (enExample)
AU (1) AU750120B2 (enExample)
BG (1) BG65212B1 (enExample)
BR (1) BR9810911A (enExample)
CA (1) CA2296036C (enExample)
CO (1) CO4990967A1 (enExample)
CY (1) CY1107047T1 (enExample)
CZ (1) CZ303045B6 (enExample)
DE (1) DE69832982T2 (enExample)
DK (1) DK0991658T3 (enExample)
ES (1) ES2258819T3 (enExample)
HR (1) HRP980397A2 (enExample)
HU (1) HU228996B1 (enExample)
ID (1) ID24669A (enExample)
IL (1) IL133784A (enExample)
MY (1) MY135057A (enExample)
NO (1) NO326827B1 (enExample)
NZ (1) NZ502296A (enExample)
PL (1) PL197884B1 (enExample)
PT (1) PT991658E (enExample)
RU (1) RU2195462C2 (enExample)
SK (1) SK286581B6 (enExample)
TR (2) TR200103545T2 (enExample)
TW (1) TW533217B (enExample)
WO (1) WO1999003879A1 (enExample)
ZA (1) ZA986358B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010009901A1 (en) * 1996-12-11 2001-07-26 Basf Aktiengesellschaft Germany Antineoplastic peptides
US6143721A (en) * 1997-07-18 2000-11-07 Basf Aktiengesellschaft Dolastatin 15 derivatives
US6686336B2 (en) 2000-02-08 2004-02-03 Federal Government As Represented By The Department Of Veterans Affaires N-terminal D(-)-penicillamine peptides as aldehyde sequestration agents
US6884869B2 (en) * 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US7256257B2 (en) * 2001-04-30 2007-08-14 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
RU2342399C2 (ru) * 2002-03-22 2008-12-27 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Производные гемиастерлина и их применение при лечении рака
US7064211B2 (en) * 2002-03-22 2006-06-20 Eisai Co., Ltd. Hemiasterlin derivatives and uses thereof
DK1545613T3 (da) * 2002-07-31 2011-11-14 Seattle Genetics Inc Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
PL2489364T3 (pl) 2003-11-06 2015-06-30 Seattle Genetics Inc Związki monometylowaliny zdolne do sprzęgania do przeciwciał
WO2006063135A2 (en) * 2004-12-09 2006-06-15 Eisai R & D Management Co., Ltd. Tubulin isotype screnning in cancer therapy using hemiasterlin analogs
EP1883627B1 (en) 2005-05-18 2018-04-18 Pharmascience Inc. Bir domain binding compounds
SG10201407457UA (en) 2006-05-16 2014-12-30 Pharmascience Inc Iap bir domain binding compounds
PE20140625A1 (es) 2007-07-16 2014-05-29 Genentech Inc ANTICUERPOS ANTI-CD79b E INMUNOCONJUGADOS HUMANIZADOS
PL2176296T3 (pl) 2007-07-16 2012-07-31 Genentech Inc Przeciwciała anty-CD79B i immunokoniugaty i sposoby stosowania
DE102007039706A1 (de) 2007-08-22 2009-02-26 Erhard Prof. Dr.-Ing. Kohn Chemischer Sensor auf Diamantschichten
PT2247620T (pt) 2008-01-31 2016-08-23 Genentech Inc Anticorpos e imunoconjugados anti-cd79b e métodos de utilização
BR112012014899A2 (pt) 2009-12-18 2017-03-14 Idenix Pharmaceuticals Inc composto, composição farmacêutica, método para tratar ou prevenir uma infecção por vírus de hepatite c em um sujeito, método para tratar , prevenir ou melhorar um ou mais sintomas de uma doença hepática ou distúrbio associado a uma infecção por vírus de hepatite c em um sujeito, método para inibir a replicação de um vírus em um hospedeiro, método para inibir a replicação de um vírus
RU2573994C2 (ru) 2010-02-10 2016-01-27 Иммьюноджен, Инк Антитела против cd20 и их применение
KR20120140658A (ko) 2010-02-12 2012-12-31 파마사이언스 인크. Iap bir 도메인 결합 화합물
US10131682B2 (en) 2012-11-24 2018-11-20 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to a cell binding molecules
CN114262344A (zh) 2014-02-28 2022-04-01 杭州多禧生物科技有限公司 带电荷链接体及其在共轭反应上的应用
DK3262071T3 (da) 2014-09-23 2020-06-15 Hoffmann La Roche Fremgangsmåde til anvendelse af anti-CD79b-immunkonjugater
CA2989269C (en) 2015-06-15 2020-09-22 Robert Yongxin Zhao Hydrophilic linkers for conjugation of a cytotoxic agent or chromophore molecule to a cell-binding molecule
CN108449940B (zh) 2015-07-12 2021-06-08 杭州多禧生物科技有限公司 与细胞结合分子的共轭偶联的桥连接体
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
CN116143678A (zh) 2016-11-14 2023-05-23 杭州多禧生物科技有限公司 偶联连接体,含有此连接体的细胞结合分子-药物偶联物及其制备和应用
MX2024002571A (es) 2021-09-03 2024-03-20 Toray Industries Composicion farmaceutica para tratamiento y/o prevencion de cancer.
KR20240095442A (ko) 2021-11-03 2024-06-25 항저우 디에이씨 바이오테크 씨오, 엘티디 항체의 특이적 접합

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816444A (en) * 1987-07-10 1989-03-28 Arizona Board Of Regents, Arizona State University Cell growth inhibitory substance
US4879278A (en) * 1989-05-16 1989-11-07 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15
SG87056A1 (en) * 1991-08-09 2002-03-19 Teikoku Hormone Mfg Co Ltd Novel tetrapeptide derivative
US5533097A (en) * 1992-02-26 1996-07-02 Motorola, Inc. Portable communication system comprising a local and wide area communication units which can store a communication when the wide area communication system is not available
US5448045A (en) * 1992-02-26 1995-09-05 Clark; Paul C. System for protecting computers via intelligent tokens or smart cards
US5831002A (en) * 1992-05-20 1998-11-03 Basf Aktiengesellschaft Antitumor peptides
HUT71398A (en) * 1992-05-20 1995-11-28 Basf Ag Derivatives of dolastatin
NZ258882A (en) * 1992-12-16 1997-06-24 Basf Ag Antineoplastic peptides and compositions thereof
US5554993A (en) * 1994-01-04 1996-09-10 Panasonic Technologies, Inc. Global position determining system and method
US5530097A (en) * 1994-08-01 1996-06-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory peptide amides
US5504191A (en) * 1994-08-01 1996-04-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide methyl esters
US5554725A (en) * 1994-09-14 1996-09-10 Arizona Board Of Regents Acting On Behalf Of Arizona State University Synthesis of dolastatin 15
US5663149A (en) * 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
US5618232A (en) * 1995-03-23 1997-04-08 Martin; John R. Dual mode gaming device methods and systems
US5970143A (en) * 1995-11-22 1999-10-19 Walker Asset Management Lp Remote-auditing of computer generated outcomes, authenticated billing and access control, and software metering system using cryptographic and other protocols
US5807984A (en) * 1995-11-09 1998-09-15 Basf Aktienegesellschaft Oligopeptides, the preparation and use thereof
TW474946B (en) * 1995-12-15 2002-02-01 Basf Ag Novel compounds, the preparation and use thereof
CA2287379C (en) * 1997-01-10 2005-10-04 Silicon Gaming-Nevada Method and apparatus for providing authenticated, secure on-line communication between remote locations
US6143721A (en) * 1997-07-18 2000-11-07 Basf Aktiengesellschaft Dolastatin 15 derivatives
US6554705B1 (en) * 1997-08-22 2003-04-29 Blake Cumbers Passive biometric customer identification and tracking system
US6629591B1 (en) * 2001-01-12 2003-10-07 Igt Smart token
US6438382B1 (en) * 2001-02-14 2002-08-20 Telefonaktiebolaget Lm Ericsson (Publ.) Expedited location determination in analog service areas

Also Published As

Publication number Publication date
JP5047935B2 (ja) 2012-10-10
US20030153505A1 (en) 2003-08-14
TR200103545T2 (tr) 2002-06-21
KR100579748B1 (ko) 2006-05-15
CZ303045B6 (cs) 2012-03-07
CN1268636C (zh) 2006-08-09
US20130046077A1 (en) 2013-02-21
CZ2000176A3 (en) 2001-06-13
HUP0004234A2 (hu) 2001-05-28
ES2258819T3 (es) 2006-09-01
US6143721A (en) 2000-11-07
TW533217B (en) 2003-05-21
HRP980397A2 (en) 1999-04-30
JP4508413B2 (ja) 2010-07-21
KR20010021998A (ko) 2001-03-15
EP0991658A1 (en) 2000-04-12
JP2009137967A (ja) 2009-06-25
JP5122429B2 (ja) 2013-01-16
IL133784A0 (en) 2001-04-30
DE69832982D1 (de) 2006-02-02
CN1264388A (zh) 2000-08-23
DE69832982T2 (de) 2006-08-24
HK1029125A1 (en) 2001-03-23
ZA986358B (en) 2000-01-17
AU750120B2 (en) 2002-07-11
CA2296036A1 (en) 1999-01-28
WO1999003879A1 (en) 1999-01-28
CO4990967A1 (es) 2000-12-26
JP2009137968A (ja) 2009-06-25
US8163698B2 (en) 2012-04-24
RU2195462C2 (ru) 2002-12-27
AU8475898A (en) 1999-02-10
SK286581B6 (sk) 2009-01-07
US20100099843A1 (en) 2010-04-22
BG65212B1 (bg) 2007-07-31
PL197884B1 (pl) 2008-05-30
JP2012211164A (ja) 2012-11-01
NO20000231L (no) 2000-01-17
PL338144A1 (en) 2000-09-25
US6458765B1 (en) 2002-10-01
ID24669A (id) 2000-07-27
BG104089A (en) 2000-12-29
CA2296036C (en) 2007-05-01
CY1107047T1 (el) 2012-09-26
HU228996B1 (hu) 2013-07-29
JP2001515010A (ja) 2001-09-18
EP0991658B1 (en) 2005-12-28
US20060270606A1 (en) 2006-11-30
DK0991658T3 (da) 2006-05-15
NO326827B1 (no) 2009-02-23
SK187999A3 (en) 2000-09-12
US7662786B2 (en) 2010-02-16
BR9810911A (pt) 2000-08-01
IL133784A (en) 2005-09-25
MY135057A (en) 2008-01-31
TR200000132T2 (tr) 2000-05-22
HUP0004234A3 (en) 2001-08-28
ATE314387T1 (de) 2006-01-15
NZ502296A (en) 2002-02-01
NO20000231D0 (no) 2000-01-17
US7084110B2 (en) 2006-08-01
PT991658E (pt) 2006-05-31

Similar Documents

Publication Publication Date Title
AR018501A1 (es) Derivados de la dolastatina 15
GEP20012413B (en) Novel Substituted Cyclic Amino Acids as Pharmaceutical Agents
MX9305444A (es) Derivados de rodanina como agentes hipoglucemicos y para el tratamiento de la enfermedad de alzheimer, composiciones farmaceuticas que los contienen y procedimiento para su preparacion.
AR011957A1 (es) Derivados de dolastatina 15 con funcionalidades carbonilo y heterociclicas en el c-terminal
DE69030100D1 (de) Peptidderivat, verfahren zu dessen herstellung, sowie dieses enthaltende pharmazeutische zusammensetzung
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
DE3851776D1 (de) Verwendung von IGF-II zur Behandlung von Knochenkrankheiten.
UY28280A1 (es) 2- hidroxi - 3- diaminoalcanos de benzamida
DK0707591T3 (da) Methylphosphonsyreestere, fremgangsmåde til deres fremstilling samt deres anvendelse
DK0490772T3 (da) 1,4-disubstituerede piperaziner, fremgangsmåde til fremstilling heraf og farmaceutiske midler, der indeholder dem
BR0213139A (pt) Composto, método de tratamento ou prevenção de doenças e de preparação de um composto, uso de um composto e composição farmacêutica
PA8432901A1 (es) Compuestos de piridilpirrol
UY28279A1 (es) Fenacilo 2 -hidroxi - 3 - diaminoalcanos
BR9607965A (pt) Composto composição farmacêutica e processo para tratar uma doença parasítica em um mamífero
ATE150301T1 (de) Aminoalkanesulfonsäurederivate und pharmazeutische zusammensetzungen davon zur prävention oder behandlung von herzerkrankungen
ES2149403T3 (es) Benciloxicarbonilguanidinas sustituidas como inhibidores del intercambiador de protones de sodio, procedimiento para su preparacion, su empleo como medicamento o agente de diagnostico, asi como medicamento que las contiene.
ATE251631T1 (de) Dipohosphonsäuresalze für die behandlung von osteoporose
BR0110396A (pt) Métodos para prevenir e tratar alopecia induzida por quimioterapia ou radioterapia
EA200001029A1 (ru) Производные гигромицина
DK160316C (da) Analogifremgangsmaade til fremstilling af beta-casomorphinanaloge peptider samt pharmakologisk acceptable syreadditionssalte og metalkomplekser deraf
CO5640064A2 (es) Citomodilacion de peptidos para tratar cistitis intersticial
MX9300203A (es) Compuestos policiclicos disubstituidos y composicion farmaceutica que los contiene.
AR031126A1 (es) Acidos amino(oxo)aceticos inhibidores de la proteina tirosina fosfatasa
ES2110057T3 (es) Composicion medicinal que contiene tcf-ii.
DE59409413D1 (de) Verwendung von n,s-diacetylcystein-ethylester (dacee) zur herstellung eines medikaments zur behandlung viraler erkrankungen

Legal Events

Date Code Title Description
FG Grant, registration